Compare Eli Lilly And Co (LLY) vs Super Micro Computer Inc (SMCI) Price & Performance

Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.

The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.

Super Micro Computer (SMCI) trades at $41.86, down 6.89% in the last session, but maintains strong fundamental momentum with three consecutive quarterly earnings beats and robust AI-driven revenue growth. The stock shows bullish technical signals with support at $40-42 levels, while valuation metrics remain attractive with P/E of 13.12 and P/S of 0.76. Recent news highlights AI server demand growth and successful NVIDIA Vera Rubin shipments, positioning SMCI as a key infrastructure player in the expanding AI market.

SMCI presents a compelling value opportunity with strong earnings momentum and AI infrastructure leadership, though investors face risks from competitive pressures and ongoing DOJ investigation. Analyst consensus targets $42.33 with 36% buy ratings, suggesting modest upside potential from current levels. The company's debt-to-asset ratio improvement from 33.93% to 29.12% indicates strengthening balance sheet management alongside projected revenue growth to $39.1B in 2026.